Responses
Regular and young investigator award abstracts
Clinical trials completed
283 Safety and efficacy signals in the complete phase I study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients refractory to immune checkpoint inhibitors (ICIs)
Compose a Response to This Article
Other responses
No responses have been published for this article.
